Eosinophilic otitis media is characterized by highly viscous middle ear effusion and associated with bronchial asthma and chronic rhinosinusitis with nasal polyps. It is difficult to treat with conventional therapy such as corticosteroid and ventilation tube insertion. We have encountered a 58-year-old patient with refractory eosinophilic otitis media who was successfully treated with dupilumab.

Eosinophilic otitis media is characterized by highly viscous middle ear effusion and associated with bronchial asthma and chronic rhinosinusitis with nasal polyps. It is difficult to treat with conventional therapy such as corticosteroid and ventilation tube insertion. We have encountered a 58-year-old patient with refractory eosinophilic otitis media who was successfully treated with dupilumab.

Eosinophilic otitis media is characterized by highly viscous middle ear effusion and associated with bronchial asthma and chronic rhinosinusitis with nasal polyps. It is difficult to treat with conventional therapy such as corticosteroid and ventilation tube insertion. We have encountered a 58-year-old patient with refractory eosinophilic otitis media who was successfully treated with dupilumab.

Eosinophilic otitis media is characterized by highly viscous middle ear effusion and associated with bronchial asthma and chronic rhinosinusitis with nasal polyps. It is difficult to treat with conventional therapy such as corticosteroid and ventilation tube insertion. We have encountered a 58-year-old patient with refractory eosinophilic otitis media who was successfully treated with dupilumab.

Eosinophilic otitis media is characterized by highly viscous middle ear effusion and associated with bronchial asthma and chronic rhinosinusitis with nasal polyps. It is difficult to treat with conventional therapy such as corticosteroid and ventilation tube insertion. We have encountered a 58-year-old patient with refractory eosinophilic otitis media who was successfully treated with dupilumab.

Recently, reports of noise-induced hearing loss (NIHL) have sharply risen among workers in South Korea, almost 20-fold in 2022, compared to 2012. This is presumably because NIHL is combined with age-related hearing loss. For the correct diagnosis of NIHL, therefore, the effect of aging that contributes to threshold shifts is should be excluded, and that would require scrutinizing of various established methods. Additionally, international and domestic data from large cross-sectional studies may provide new insights in excluding the effect of age-related hearing loss in individuals in which threshold shifts occurred. This paper comprises the recommendations for the diagnosis and quantification of NIHL in a medico-legal context.

Background and Objectives: Cognitive behavioral therapy (CBT) is a treatment option for subjective tinnitus. There are many reports on its clinical efficacy, but the protocol has not been well established. The purpose of this study was to set an outpatient-based CBT protocol and evaluate its clinical efficacy for tinnitus.Subjects and Method A total of 85 chronic tinnitus patients was assessed in this prospective study. After evaluating for eligibility, 30 patients completed CBT based on a protocol of 5 weekly sessions in an outpatient setting. Therapeutic efficacy was assessed by Tinnitus Handicap Inventory (THI) questionnaires and visual analogue scale (VAS) for tinnitus. The initial scores were compared with the final scores, which were assessed a month after the fifth CBT session. Results: The results showed that CBT reduced THI and VAS scores significantly (p<0.05). Conclusion The results of the study suggest that an outpatient-based CBT protocol can be clinically beneficial for patients with tinnitus.

In rare cases, antiresoprtive medications for osteoporosis cause osteonecrosis. Necrotic bone lesions localized at the jaw after the use of antiresorptive medications is named medicationrelated osteonecrosis of the jaw (MRONJ). Although some cases with MRONJ affect the paranasal sinus, inferior turbinate necrosis have not been reported in South Korea yet. Here, we report a case of inferior turbinate osteonecrosis that developed after denosumab had been used.

Background: and PurposeResponses to oral appliances (OAs) in obstructive sleep apnea (OSA) vary, and have not been fully evaluated in Korean patients. In this study we aimed to determine the efficacy of OAs for the first-line treatment of Korean patients with moderate or severe OSA. Methods: This multicenter prospective observational study included 45 patients with moderate or severe OSA that had been newly diagnosed between March 2017 and May 2018 and who underwent OA treatment for 1 month. Questionnaires were completed and polysomnography (PSG) was performed before and after OA treatment. The primary outcome measures were improvement in the absolute apnea-hypopnea index (AHI) and the percentage reduction in the AHI. The secondary outcomes were improvements in the questionnaire scores related to sleep-associated symptoms and PSG parameters. Results: The patients were aged 47.4±12.1 years (mean±SD), only two of them were female, and their AHI at baseline was 29.7±10.9/h. After OA treatment the AHI had reduced by 63.9±25.8%, with the reduction was similar between the patients with moderate OSA and those with severe OSA. Overall 31.1% of the patients achieved a normal AHI (<5/h), and 64.4% had an AHI of ≤10/h after the treatment. The body mass index (BMI) was the most reliable factor for predicting the percentage reduction in the AHI. The OAs also improved the sleep architecture and subjective sleep-related symptoms. Conclusions The OAs were effective in patients with moderate or severe OSA. The OAs reduced the mean AHI to 63.9% of the baseline value, and this reduction was influenced by the BMI.